FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk
March 17, 2017 10:29 ET
|
National Lipid Association
WASHINGTON, DC--(Marketwired - March 17, 2017) - The FOURIER trial lead investigators announced today that the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events by...